Celine Halioua is the CEO and Founder of Loyal, a biotech startup developing drugs to increase healthspan, the period of life spent in good health.
Before founding Loyal, she was a DPhil student at Oxford studying the economics of gene therapy. She sought to understand the incentives of different healthcare systems in providing curative therapeutics. This fed a broader interest in health equality that led her to longevity and preventative medicine. Celine dropped out of her DPhil in her final year to join Laura Deming at the Longevity Fund, one of the pioneering early investors in the longevity field, before founding Loyal in 2019 at the age of 25.
Programming descriptions are generated by participants and do not necessarily reflect the opinions of SXSW.